Guillain-Barré syndrome (GBS) occurs when the immune system attacks part of the nerves in the peripheral nervous system. Below are COVID news and research updates that specifically relate to GBS.
Yesterday, Johnson & Johnson COVID-19 vaccine supplier Janssen Biotech, Inc. released a statement regarding the potential risks of their adenovirus vaccine. The updated disclaimer states:
Read More »Israel is now the first country whose Ministry of Health is officially recommending the use of booster shots for those with compromised immune systems, who may be unable to develop sufficient antibodies after a full dose of the vaccine.
Read More »Recently, reports have been published associating adenovirus vector COVID-19 vaccines and the onset of unusual variants of Guillain-Barré syndrome (GBS). Notably, experts highlight that there have been no findings suggesting COVID vaccines cause GBS. However, the timing of the condition’s onset occurring shortly after vaccination has raised questions among researchers.
Read More »The group at the Zabludowicz Center for Autoimmune Diseases of the Sheba Medical Center and the Laboratory of the Mosaic of Autoimmunity at Saint Petersburg State University have comprehensively investigated and reported the association between various common pathogenic viruses and the development of autoimmune and chronic inflammatory diseases. In light of the current global pandemic, they have also shifted their focus to include a recent (December 2020) review of the appearance of autoimmune diseases reported to be triggered by a SARS-CoV-2 infection.
Read More »